Stay updated with breaking news from Mark Litton. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Exploratory findings add to increasing body of clinical and preclinical data supporting positive modulation of the neurotrophic HGF system as a potential therapeutic approach for neurodegenerative...
Continues to report clinical and preclinical findings supporting the potential benefits of its small molecule therapeutic candidates targeting the...
Veteran biopharmaceutical executive brings over 30 years of financial, corporate strategy, transactional and business development experienceBOTHELL, Wash., May 22, 2023 -- Athira Pharma,... | May 22, 2023
Phase 2/3 LIFT-AD trial of fosgonimeton for mild-to-moderate Alzheimer’s disease to focus on 40 mg dose Open label extension trial to be extended, providing up to 36 months of long-term... | May 11, 2023
BOTHELL, Wash., Jan. 31, 2023 -- Athira Pharma, Inc. , a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration,... | January 31, 2023